Chief Executive Officer, Swedish Orphan Biovitrum Ab Publ Sobi
Search every verified Guido Oelkers interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Guido Oelkers, CEO of Swedish Orphan Biovitrum (Sobi), discussed the company's Q2 2020 results during a July 2020 webcast. He noted that the COVID-19 pandemic created a difficult environment, citing U.S. data showing total prescriptions down 6-12% and new prescriptions down 30-40% between late May and early June. Oelkers stated that the launch of the product clds was delayed to late Q3 or beginning of Q4 2020 due to COVID-19 supply chain issues, and that the company expected to be in a good position for it by early 2021. He also mentioned that the company was rethinking geographic diversification for HLH patients in markets like China and Japan, where the company planned to take ownership itself. Oelkers reported that during Q2, the company had a net patient gain with minimal switches from its product to competitors. He characterized the Q2 results as solid and the business as robust, despite the challenging environment.
Sign in to search the full transcript archive, filter by topic, and access every quote from Guido Oelkers.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →